OCS Oculis Holding AG

Nasdaq oculis.com


$ 19.30 $ -0.15 (-0.77 %)    

Wednesday, 12-Nov-2025 09:48:57 EST
QQQ $ 619.96 $ -4.82 (-0.77 %)
DIA $ 483.66 $ 3.10 (0.65 %)
SPY $ 683.27 $ -1.52 (-0.22 %)
TLT $ 90.04 $ 0.09 (0.1 %)
GLD $ 380.71 $ 0.56 (0.15 %)
$ 19.4
$ 19.45
$ 19.15 x 100
$ 19.49 x 100
$ 19.30 - $ 19.30
$ 14.00 - $ 23.08
162,256
na
318.13M
$ 0.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-oculis-holding-maintains-51-price-target

Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:OCS) with a Buy and maintains $51 price target.

 hc-wainwright--co-maintains-buy-on-oculis-holding-raises-price-target-to-42

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $3...

 needham-reiterates-buy-on-oculis-holding-maintains-36-price-target

Needham analyst Serge Belanger reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $36 price target.

 correction-oculis-holding-q3-eps-040-beats-050-estimate-sales-303761k-beat-250000k-estimate

Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.50)...

 oculis-raises-110m-through-oversubscribed-offering-to-advance-privosegtor-clinical-development-and-strengthen-ophthalmology-pipeline

Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotectiv...

 chardan-capital-maintains-buy-on-oculis-holding-raises-price-target-to-51

Chardan Capital analyst Daniil Gataulin maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $3...

 hc-wainwright--co-maintains-buy-on-oculis-holding-raises-price-target-to-36

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $3...

 oculis-advances-privosegtor-into-fda-backed-pivotal-trials-aiming-to-deliver-first-neuroprotective-therapy-for-vision-loss

Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing neuro-o...

 oculis-reports-trial-results-showing-vision-gains-in-patients-with-acute-optic-neuritis

Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations for ophthalmic and...

 needham-initiates-coverage-on-oculis-holding-with-buy-rating-announces-price-target-of-36

Needham analyst Serge Belanger initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rating and announces Price Targe...

 hc-wainwright--co-maintains-buy-on-oculis-holding-raises-price-target-to-33

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $3...

 oculis-holding-q2-eps-057-misses-053-estimate-sales-307417k-beat-250000k-estimate

Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.5...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION